GlassScriptPhysician profile
Bailey S Barrineau
NPI 1467050138
$4,337.52
in general payments reported to CMS, 2019-2025
29 companies · $907 in 2025
The $907 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $988 · 2022: $1,161 · 2023: $625 · 2024: $656 · 2025: $907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,143 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,143.00 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $944.89 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $756.57 | 2021-2025 | Mounjaro, Jardiance, Trulicity |
| Novo Nordisk INC | $316.56 | 2021-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $292.18 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbvie INC. | $261.40 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $251.14 | 2022-2025 | |
| Glaxosmithkline, LLC. | $216.84 | 2021-2025 | Trelegy Ellipta |
| Abbott Laboratories | $200.34 | 2021-2024 | Freestyle Libre, Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.43 | 2021-2025 | Jardiance |
| Pfizer INC. | $119.32 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $91.46 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $88.82 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $85.85 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $71.55 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.41 | 2024-2025 | Xifaxan |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $57.09 | 2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $52.88 | 2021 | |
| Corcept Therapeutics | $44.83 | 2025 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.08 | 2022-2023 | |
| Vanda Pharmaceuticals INC. | $30.95 | 2021 | |
| Biodelivery Sciences International, INC. | $28.96 | 2021 | |
| Sumitomo Pharma America, INC. | $24.38 | 2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $23.52 | 2021 | |
| Jazz Pharmaceuticals INC. | $21.73 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.55 | 2022 | |
| Optinose US, INC. | $20.91 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $19.48 | 2025 | Rexulti |
| Esperion Therapeutics, INC. | $12.01 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bailey Barrineau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.